CHIORAZZI, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 11.857
EU - Europa 6.708
AS - Asia 3.739
SA - Sud America 135
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 23
AF - Africa 20
Totale 22.521
Nazione #
US - Stati Uniti d'America 11.642
IT - Italia 1.518
SG - Singapore 1.385
DE - Germania 1.268
CN - Cina 1.241
SE - Svezia 942
IE - Irlanda 814
RU - Federazione Russa 653
UA - Ucraina 523
HK - Hong Kong 471
GB - Regno Unito 317
CA - Canada 200
VN - Vietnam 195
AT - Austria 152
FI - Finlandia 147
ID - Indonesia 129
DK - Danimarca 114
BR - Brasile 112
FR - Francia 107
IN - India 89
JP - Giappone 64
TR - Turchia 49
BE - Belgio 45
NL - Olanda 38
KR - Corea 34
EU - Europa 23
AU - Australia 21
MY - Malesia 20
IR - Iran 18
NZ - Nuova Zelanda 18
ES - Italia 14
TW - Taiwan 10
MX - Messico 9
PL - Polonia 9
CH - Svizzera 8
EG - Egitto 8
AE - Emirati Arabi Uniti 7
HU - Ungheria 7
SA - Arabia Saudita 7
CZ - Repubblica Ceca 6
HR - Croazia 6
AR - Argentina 5
UZ - Uzbekistan 5
BG - Bulgaria 4
RO - Romania 4
BO - Bolivia 3
CL - Cile 3
CO - Colombia 3
PK - Pakistan 3
PT - Portogallo 3
RS - Serbia 3
VE - Venezuela 3
AO - Angola 2
BD - Bangladesh 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EC - Ecuador 2
GT - Guatemala 2
LB - Libano 2
LV - Lettonia 2
NG - Nigeria 2
PY - Paraguay 2
SC - Seychelles 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EE - Estonia 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
MA - Marocco 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 22.521
Città #
Ann Arbor 2.859
Singapore 1.126
Dublin 793
Woodbridge 773
Chandler 772
Frankfurt am Main 743
Wilmington 634
Houston 580
Milan 568
Fairfield 565
Dearborn 547
Jacksonville 539
Ashburn 454
Hong Kong 434
New York 374
Santa Clara 336
Princeton 302
Nanjing 232
Seattle 231
Boardman 179
Cambridge 161
Shanghai 150
Vienna 143
Jakarta 127
Beijing 100
Dong Ket 92
Guangzhou 86
Lachine 85
Lawrence 78
Altamura 73
Council Bluffs 72
Nanchang 72
Shenyang 72
Andover 51
Carate Brianza 49
Chicago 48
Rome 45
Helsinki 44
Falls Church 43
Toronto 43
Hangzhou 41
Pune 40
Fremont 39
Jinan 39
Ottawa 39
San Diego 38
Brussels 36
Jiaxing 35
Los Angeles 35
Kunming 34
Tianjin 30
Zhengzhou 30
Changsha 29
Hebei 29
Melzo 27
Nürnberg 27
Grafing 26
Norwalk 26
Sacramento 24
London 23
Nuremberg 23
Bergamo 22
Florence 22
Shangdi 22
Mountain View 20
Ningbo 20
Dallas 19
Edmonton 18
Phoenix 17
Taizhou 17
Tokyo 17
Leawood 16
Codroipo 15
Hefei 15
Lissone 15
Philadelphia 15
Washington 15
Mainz 13
São Paulo 13
Lappeenranta 12
Pasir Mas 12
Shinjuku 12
Bologna 11
Cagliari 11
Kiev 11
Paris 11
Wuhan 11
Catania 10
Daejeon 10
Romola 10
Sesto San Giovanni 10
Canazei 9
Changchun 9
Como 9
Fuzhou 9
Huizen 8
Melbourne 8
Munich 8
Chongqing 7
Desio 7
Totale 15.861
Nome #
Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy 312
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 305
Age-related changes in the function and structure of the peripheral sensory pathway in mice 302
Global transcriptomic profile of dorsal root ganglion and physiological correlates of cisplatin-induced peripheral neuropathy 297
Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights 293
Studio della neurotossicità periferica indotta da farmaci antitubulinici in modelli sperimentali in vitro e in vivo 278
An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection 277
Artificial apolipoprotein corona enables nanoparticle brain targeting 267
Anti-tumor efficacy assessment of the sigma receptor pan modulator RC-106. A promising therapeutic tool for pancreatic cancer 255
Executive control in schizophrenia: a preliminary study on the moderating role of COMT Val158Met for comorbid alcohol and substance use disorders 252
Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models 247
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 241
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 226
Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity 219
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 217
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 210
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 208
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 203
Neutrophil depletion affects Dark Agouti Experimental Autoimmune Encephalomyelitis 199
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse 198
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 198
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 194
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors 191
The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity 191
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats 188
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 186
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 183
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats 182
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 182
Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model 181
Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE 181
Oxidative stress and inflammation induced by acute and subacute ultrafine exposure: contrinbution to alzheimer's disease 181
Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system 176
Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats 176
Islet transplantation and insulin administration relieve long-term complications and rescue the residual endogenous pancreatic β cells 174
OCT2 transporter involvement in development of cisplatin toxicity 174
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity 174
The ventral caudal nerve: a physiologic-morphometric study in three different rat strains 173
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 173
In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™) 171
Facial emotion recognition in schizophrenia: An exploratory study on the role of comorbid alcohol and substance use disorders and COMT Val158Met 170
Bortezomib-Induced Peripheral Neurotoxicity: a Preclinical Model to Study Neuropathic Pain in Rat 167
Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: An in vitro study 166
Paclitaxel: Chemotherapy and Neurotoxicity – The Two sides of the Coin 166
Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies 165
MSCs ameliorate clinical course in rats with experimental autoimmune encephalomyelitis 165
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity 164
Platinum-Taxane combination chemotherapy: assessment of electrophysiologic pathologic and morphometric fetures in chronic wistar rat models 164
Current view in platinum drug mechanisms of peripheral neurotoxicity 163
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 163
Lipoplatin tm: a less neurotoxic formulation of cisplatin 161
Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats 159
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies 159
Cr4056: a novel potent anti-nociceptive agent for several animal models of neuropathic pain 157
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 156
Multiple Neuroprotective Mechanisms of Mesenchymal Stem Cells 155
Reply to a comment paper on the published paper by canta, a. Et al: “calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity”—antioxidants 2020, 9, 594 154
Characterization in vivo of two different molecular mechanisms involved in the development of bortezomib-induced peripheral neuropathy 153
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 152
Granulocytes in actively induced Lewis rat EAE 151
Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model 146
Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice 143
Organic cation transporter 2 mRNA expression in dorsal root ganglia neurons 142
The role of the complete Freund’s adjuvant and neutrophils in actively induced Lewis rat EAE 141
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 141
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 141
Oxaliplatin induces pH acidification in dorsal root ganglia neurons 139
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 139
Ethoxyquin is effective in preventing cisplatin-induced painful peripheral neuropathy in rats 138
Effectiveness of MSC therapeutic administration on rats affected by chronic Experimental Autoimmune Encephalomyelitis 138
Positive effect of Mesenchymal Stem Cells therapeutic administration on chronic Experimental Autoimmune Encephalomyelitis 137
Preventive treatment with anti-rat neutrophil serum affects the relapsing phase in Dark Agouti EAE rats 137
A Possible role of OCT2 gene in the development of peripheral neurotoxicity induced by cisplatin 136
Effect of preventive and therapeutic treatment of ghrelin agonist HM01 on the peripheral neurotoxicity induced by bortezomib in wistar rats. 136
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 135
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 135
Epothilone B-induced toxic effects on peripheral nervous system: in vitro and in vivo experimental models 134
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 134
Multimodal experimental approach to the study of human neurological diseases 133
ANALGELSIC EFFECT OF BUPRENORPHINE IN AN EXPERIMENTAL MODEL OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY 132
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? 132
MSCs effect on Dark Agouti rats affected by chronic EAE 131
Characterization of bortezomib-induced peripheral neuropathy in an immune-suppressed murine model 131
Neutrophil depletion during sensitization phase affects the chronic phase of Experimental Autoimmune Encephalomyelitis 131
Evaluation of microtubule polimerization involved in the development of bortezomib-induced peripheral neuropathy through new in vitro and in vivo models 130
Genetic factors influencing the development of vincristine-induced neurotoxicity 130
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 130
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy 129
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 129
Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve 128
BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY: STUDY OF PROTEASOME INHIBITION AND MICROTUBULE STABILIZATION MECHANISMS IN RAT MODEL 128
Co-trasplantation of Pancreatic Islets with Mesenchymal Stem Cells promotes the functional recovery of diabetic neuropathy in vivo 128
Human Immunoglobulins ameliorate pain in rats with bortezomib-induced peripheral neuropathy 127
Bortezomib-induced neuropathic pain: evaluation of antinociceptive effect of a new analgesic compound 126
Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function 126
Pain-related behaviour and analgesic effect of gabapentin in an experimental model of bortezomib-induced neuropathic pain 124
CISPLATIN, EPOTHILONE B AND BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHIES: A NEUROPHYSIOLOGICAL STUDY IN THE MOUSE. 122
Oxaliplatin-Induced Peripheral Neurotoxicity: Morphological Characterization In Different Mouse Strains 118
Characterization of the neurotoxicity and antineoplastic activity of bortezomib in a new myeloma-bearing murine model. 118
Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage? 117
Totale 17.137
Categoria #
all - tutte 86.275
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.275


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.203 0 0 0 0 0 0 0 248 334 319 247 55
2020/20213.424 147 132 377 353 262 306 408 321 290 258 204 366
2021/20221.946 152 234 171 177 139 181 95 106 82 143 134 332
2022/20233.484 389 846 380 332 259 540 63 181 277 51 104 62
2023/20242.986 97 98 101 146 386 725 508 163 158 68 68 468
2024/20254.045 452 898 712 367 624 294 512 186 0 0 0 0
Totale 23.965